Last updated: October 11, 2026
PF-07081532, also known as lotiglipron, was Pfizer’s oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity. Pfizer discontinued the program in 2023 after a clinical study identified liver-enzyme elevations. The asset has no active development path, no FDA approval, no Orange Book listing, and no credible standalone commercial revenue forecast. Its market value is effectively zero unless Pfizer or a third party revives the molecule after new safety and dose-selection work.
What is PF-07081532?
PF-07081532 was an orally administered, non-peptide GLP-1 receptor agonist discovered and developed by Pfizer. It was designed to activate the GLP-1 receptor without the injection requirements associated with injectable semaglutide, tirzepatide, and related products.
| Attribute |
PF-07081532 |
| Generic name |
Lotiglipron |
| Developer |
Pfizer |
| Molecular class |
Oral small-molecule GLP-1 receptor agonist |
| Primary targets |
Type 2 diabetes and obesity |
| Route |
Oral |
| Development status |
Discontinued |
| FDA approval |
None |
| FDA regulatory exclusivity |
None |
| Orange Book listing |
None |
| Commercial sales |
None |
| Key development issue |
Liver-enzyme elevations |
| Principal competitive products |
Wegovy, Ozempic, Rybelsus, Mounjaro, Zepbound |
PF-07081532 was distinct from Pfizer’s other oral GLP-1 candidate, danuglipron, also known as PF-06882961. Pfizer continued to evaluate danuglipron after stopping lotiglipron, although danuglipron also faced development and tolerability challenges.
Why did Pfizer discontinue PF-07081532?
Pfizer stopped PF-07081532 development after a Phase 2 study in people with type 2 diabetes showed elevations in alanine aminotransferase and aspartate aminotransferase, commonly referred to as ALT and AST.
The company disclosed the decision in June 2023. Pfizer stated that the liver-enzyme findings were observed without evidence of liver dysfunction, but the overall safety profile did not support continuing the program. The decision was a clinical-development termination rather than a regulatory rejection.
Development timeline
| Date |
Event |
| 2021-2022 |
PF-07081532 entered early clinical development as an oral GLP-1 receptor agonist |
| 2022 |
Pfizer evaluated the candidate in Phase 1 and Phase 2 studies involving diabetes and obesity-related endpoints |
| June 2023 |
Pfizer discontinued PF-07081532 after liver-enzyme elevations in a Phase 2 study |
| 2023 onward |
Pfizer redirected oral GLP-1 investment toward danuglipron and other metabolic programs |
| Current status |
No active public clinical-development program for lotiglipron |
Pfizer’s decision was commercially significant because the asset was intended to compete in a rapidly expanding obesity market where an effective oral GLP-1 product could command substantial demand. The safety signal removed Pfizer’s most advanced second oral small-molecule GLP-1 program from that competitive field.
What clinical data were reported for PF-07081532?
Public disclosures indicated that PF-07081532 produced pharmacologic activity consistent with GLP-1 receptor agonism, including effects on glucose control and body weight. The available public record did not establish a clinically competitive benefit-risk profile sufficient to support Phase 3 development.
The program’s principal limitation was safety rather than a demonstrated lack of GLP-1 efficacy. Pfizer did not disclose a comprehensive late-stage efficacy package before termination, and no pivotal registration study was initiated.
Publicly reported clinical characteristics
- Oral, once-daily administration was part of the development concept.
- The candidate was evaluated in patients with type 2 diabetes.
- Weight reduction was assessed as an obesity-related development objective.
- Liver-enzyme elevations emerged during clinical testing.
- Pfizer did not advance the candidate into confirmatory Phase 3 trials.
- No long-term cardiovascular outcomes program was initiated.
The absence of Phase 3 data prevents a reliable comparison with the approved efficacy profiles of semaglutide and tirzepatide.
What is the FDA status of PF-07081532?
PF-07081532 has no FDA approval, no New Drug Application approval, and no FDA-recognized commercial exclusivity.
FDA and regulatory status
| Regulatory issue |
Status |
| Investigational status |
Clinical-stage asset only |
| Approved indication |
None |
| NDA approval |
None |
| FDA label |
None |
| REMS |
None |
| New chemical entity exclusivity |
None |
| Orphan-drug exclusivity |
None |
| Pediatric exclusivity |
None |
| Orange Book listing |
None |
| ANDA litigation pathway |
Not applicable |
The candidate therefore has no approved-label protection and no practical regulatory barrier to development by another sponsor, subject to patent rights, clinical data rights, and manufacturing considerations.
What patents protect PF-07081532?
Publicly available information does not establish an active, commercially meaningful patent estate that could support a launch forecast for lotiglipron after the clinical program’s termination.
Pfizer likely filed patent applications covering one or more of the following:
- The PF-07081532 chemical entity
- Markush compounds and related GLP-1 receptor agonists
- Pharmaceutical compositions
- Oral dosage forms
- Methods of treating diabetes
- Methods of reducing body weight
- Manufacturing processes and intermediates
Patent-family identification requires a verified search of USPTO, WIPO, EPO, and national registers using the compound code, lotiglipron, chemical structure, and Pfizer assignee records. The public development record alone does not establish which applications matured into granted patents, which claims remain enforceable, or whether any family covers the clinical compound specifically.
Patent-life assessment
| Patent category |
Public commercial impact |
| Compound patents |
Potentially relevant, but no verified enforceable claim set established here |
| Formulation patents |
No approved formulation exists |
| Method-of-use patents |
No approved indication exists |
| Manufacturing patents |
Could restrict production, but no public launch program exists |
| Orange Book patents |
None |
| Patent litigation |
No material public Paragraph IV dispute identified |
| Settlement agreements |
None publicly associated with lotiglipron |
Because PF-07081532 never reached approval, patent expiration dates do not create a conventional generic-entry timeline. Any future revival would depend on the remaining patent term, patent prosecution outcomes, freedom-to-operate analysis, and the sponsor’s ability to resolve the liver-safety issue.
Were there Paragraph IV challenges or patent litigation?
No material Paragraph IV litigation or generic patent challenge is publicly associated with PF-07081532.
Paragraph IV litigation normally follows an approved small-molecule product and Orange Book-listed patents. PF-07081532 did not reach that stage. A future developer would more likely face ordinary patent-validity, infringement, and freedom-to-operate issues than an ANDA-based challenge to an approved reference product.
No public settlement agreement between Pfizer and a generic manufacturer has been associated with lotiglipron.
How does PF-07081532 compare with danuglipron?
Danuglipron was Pfizer’s principal remaining oral small-molecule GLP-1 program after the termination of lotiglipron. The two candidates should not be treated as the same asset.
| Factor |
PF-07081532, lotiglipron |
PF-06882961, danuglipron |
| Developer |
Pfizer |
Pfizer |
| Modality |
Oral small molecule |
Oral small molecule |
| Receptor target |
GLP-1 receptor |
GLP-1 receptor |
| Development status |
Discontinued |
Continued in development after lotiglipron termination |
| Key safety issue |
Liver-enzyme elevations |
Gastrointestinal tolerability and dosing challenges |
| Commercial status |
No approval |
No approval |
| Market opportunity |
No current opportunity absent revival |
Potential oral GLP-1 opportunity |
| Competitive position |
Removed from active pipeline |
Competing against oral semaglutide and future oral incretins |
Pfizer announced in late 2023 that it discontinued a once-daily formulation of danuglipron after liver-enzyme elevations, while continuing to evaluate a twice-daily formulation. This later development increased the strategic importance of Pfizer’s oral metabolic portfolio but did not revive lotiglipron.
What is the market outlook for PF-07081532?
The direct market outlook is zero under the current discontinued status. PF-07081532 has no approval, no launch date, no reimbursed indication, and no projected revenue stream.
Its former target market remains attractive. Global demand for obesity and diabetes medicines is being driven by:
- High prevalence of obesity and type 2 diabetes
- Durable weight-loss effects from GLP-1 and GIP therapies
- Expansion of treatment beyond diabetes
- Limited injectable capacity
- Patient demand for oral administration
- Reimbursement expansion in selected markets
- Use of chronic cardiometabolic therapies in earlier disease
The commercial opportunity is therefore tied to the mechanism and route, not to the discontinued lotiglipron asset.
Market comparison
| Product |
Sponsor |
Route |
Status |
Commercial relevance |
| Wegovy, semaglutide |
Novo Nordisk |
Injectable |
Approved for obesity |
Major obesity product |
| Ozempic, semaglutide |
Novo Nordisk |
Injectable |
Approved for type 2 diabetes |
Major diabetes product |
| Rybelsus, semaglutide |
Novo Nordisk |
Oral |
Approved for type 2 diabetes |
Established oral GLP-1 benchmark |
| Mounjaro, tirzepatide |
Eli Lilly |
Injectable |
Approved for type 2 diabetes |
Major incretin product |
| Zepbound, tirzepatide |
Eli Lilly |
Injectable |
Approved for obesity |
Major obesity product |
| PF-07081532, lotiglipron |
Pfizer |
Oral |
Discontinued |
No current revenue |
| Danuglipron |
Pfizer |
Oral |
Development-stage |
Potential but unproven |
Rybelsus establishes that an oral GLP-1 product can achieve commercial adoption. However, lotiglipron would have needed competitive weight loss, acceptable gastrointestinal tolerability, clean hepatic safety, convenient dosing, and reliable manufacturing to challenge semaglutide and tirzepatide.
What generic entry risks exist for PF-07081532?
There is no conventional generic-entry risk because no reference product exists. The relevant risk is asset revival risk.
A competitor seeking to develop lotiglipron or a structurally similar molecule could face:
- Pfizer composition-of-matter patent claims, if enforceable claims remain.
- Formulation or salt-form patents.
- Method-of-use patents for diabetes or obesity.
- Manufacturing-process patents.
- Clinical-development risk from the prior liver-enzyme signal.
- Regulatory requirements for repeat liver-safety monitoring.
- Competitive pressure from approved GLP-1 and GIP products.
- Pricing and reimbursement pressure in obesity treatment.
A generic manufacturer cannot file a standard ANDA for PF-07081532 because there is no approved reference drug. A future sponsor would need an independent development and regulatory strategy unless it acquired usable Pfizer data and rights.
Could PF-07081532 be revived or licensed?
A revival is possible in principle but commercially unlikely based on the available public record. Pfizer could license or sell the asset, but a transaction would require a convincing explanation of the hepatic signal and a viable clinical plan.
Potential transaction structures
- Out-license to a company specializing in oral metabolic drugs
- Asset sale with clinical-data transfer
- Regional licensing after new toxicology review
- Combination development with another metabolic agent
- Reformulation or modified-release development
- Repositioning for a narrower diabetes population
No public licensing deal has established a new owner or active development partner for lotiglipron.
A buyer would likely discount the asset heavily because it has no human proof-of-concept package suitable for registration, no approval, no commercial supply chain, and a known safety concern. The asset’s value would derive mainly from chemical know-how, patent rights, and historical clinical data.
What manufacturing and intellectual-property barriers apply?
Oral small-molecule GLP-1 programs face manufacturing barriers that differ from conventional generic tablets.
Potential technical constraints include:
- Low or variable oral bioavailability
- Food-effect sensitivity
- Dose escalation requirements
- High active pharmaceutical ingredient loading
- Solid-state and polymorph control
- Metabolite characterization
- Exposure-related tolerability
- Scale-up reproducibility
- Stability and tablet dissolution
- Drug-drug interaction assessment
PF-07081532’s development termination means Pfizer did not establish commercial-scale manufacturing for an approved product. Any future sponsor would need to reproduce the molecule, characterize impurities and metabolites, and establish a new clinical-quality manufacturing process.
What is the revenue exposure for Pfizer?
PF-07081532 did not generate product revenue. Its financial exposure was development investment and the loss of a potential position in the oral obesity market.
The opportunity cost was substantial because the obesity market expanded rapidly while Pfizer’s oral GLP-1 portfolio encountered setbacks. Pfizer’s remaining oral incretin strategy became concentrated around danuglipron and other pipeline assets rather than lotiglipron.
A direct revenue estimate for PF-07081532 is therefore:
| Revenue category |
Projection |
| Current product sales |
$0 |
| Near-term sales |
$0 |
| Sales without program revival |
$0 |
| Sales from a successful revival |
Not supportable from public data |
| Royalty revenue |
None publicly identified |
Key Takeaways
- PF-07081532, or lotiglipron, was an oral small-molecule GLP-1 receptor agonist developed by Pfizer.
- Pfizer discontinued the program in 2023 after liver-enzyme elevations in a Phase 2 study.
- The candidate has no FDA approval, Orange Book listing, regulatory exclusivity, or commercial revenue.
- No material Paragraph IV challenge, patent litigation, or settlement agreement is publicly associated with the asset.
- Patent rights may exist around the compound, formulations, uses, and manufacturing methods, but they do not create a conventional generic-entry timeline.
- The former target market remains large, but the commercial opportunity belongs to active oral GLP-1 programs rather than lotiglipron.
- Any revival would require a new safety strategy, adequate patent term, clinical investment, and a sponsor willing to compete against semaglutide and tirzepatide.
FAQs
Is PF-07081532 the same drug as danuglipron?
No. PF-07081532 is lotiglipron. Danuglipron is PF-06882961. Both are Pfizer oral small-molecule GLP-1 receptor agonists, but they are separate compounds.
Can patients obtain PF-07081532?
No. PF-07081532 is not an approved medicine and is not commercially available through ordinary prescribing channels.
Did PF-07081532 reach Phase 3?
No. Pfizer discontinued the program before pivotal Phase 3 development.
Does PF-07081532 have an estimated patent expiration date?
A reliable expiration date cannot be assigned from the public development record alone. The relevant date would depend on the specific compound patent family, filing date, patent term adjustment, patent term extension, and claim coverage.
Is PF-07081532 a potential generic competitor to Rybelsus?
No. PF-07081532 is a discontinued investigational compound, not a generic version of oral semaglutide. Any future development would require a separate regulatory pathway.
References
-
Pfizer Inc. (2023). Pfizer provides update on clinical development program for oral GLP-1 receptor agonist PF-07081532. Pfizer investor and corporate communications.
-
Pfizer Inc. (2023). Pfizer announces topline results from Phase 2 study of danuglipron and updates oral GLP-1 development strategy. Pfizer investor and corporate communications.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
Novo Nordisk. (2024). Wegovy, Ozempic, and Rybelsus prescribing information. Novo Nordisk.
-
Eli Lilly and Company. (2024). Mounjaro and Zepbound prescribing information. Eli Lilly and Company.